Aarti Drugs Ltd. (BSE: 524348) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹3,618 Cr, it ranks #972 by market cap among the 6,137 Indian listed companies on FinBizNet, and #31 of 86 in Medicinal Chemicals and Botanical Products. At ₹374.90 (as of 25 Oct 2026), the share price is 29.8% below its 52-week high of ₹534.00 and 17.5% above its 52-week low of ₹318.95. The share price is down 28.5% over one year and down 7.3% over three months.
| Current Price | ₹374.90 |
|---|---|
| Market Cap | ₹3,618 Cr |
| BSE Code | 524348 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 18.7 |
| Return on Equity | 13.36% |
| Return on Assets | 5.62% |
| 52-Week Range | ₹318.95 – ₹534.00 |
| 1-Year Price Change | -28.5% |
| 3-Month Price Change | -7.3% |
| Beta (1Y) | 0.25 |
| Dividend Yield | 0.50% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.aartidrugs.co.in |
| Revenue | ₹703 Cr |
|---|---|
| Net Profit | ₹50 Cr |
| Net Margin | 7.1% |
| EPS (Basic) | ₹5.49 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfon
1. Bulk Drugs-This segment manufactures and sells active pharmaceutical ingredients. 2. Others-This segment engages in the manufacture and sale of bulk drugs and its intermediates. 3. Pharmaceuticals-0
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Aarti Drugs Ltd. | ₹3,618 Cr | 18.7 | 13.36% | ₹703 Cr | -28.5% |
Listed by market capitalisation. Ratios are shown for context only.
Aarti Drugs Ltd. is trading at ₹374.90, with a market capitalisation of ₹3,618 Cr.
Aarti Drugs Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Aarti Drugs Ltd. has a P/E of 18.7 and a return on equity of 13.36%.
Aarti Drugs Ltd. is listed on the BSE under the scrip code 524348.
Aarti Drugs Ltd.'s share price is down 28.5% over one year and down 7.3% over three months. Its 52-week range is ₹318.95 to ₹534.00.
In Q1 FY27, Aarti Drugs Ltd. reported revenue of ₹703 Cr and net profit of ₹50 Cr, with basic EPS of ₹5.49 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.